Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01655225 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3023414 in Participants With Advanced Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 156
- Enrollment target
NCT01655225 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 156 participants.
The verdict
NCT01655225, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 156 participants
- Enrollment target
Study Summary
The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer. The study will also explore the changes to various markers in blood cells and potentially tumor cells. Finally, the study will help document any antitumor activity this drug may have. In Part A of this study, participants with advanced/metastatic cancer (including lymphoma) will receive increasing doses of LY3023414. In Part B, LY3023414 will be explored in different types of cancer, including breast and lung cancer, lymphoma and mesothelioma.
Interventions
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Midazolam
- DRUG Fulvestrant
- DRUG LY3023414
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2012-07-31 |
| Est. Completion | 2022-02-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01655225
The ClinicalTrials.gov registry entry for NCT01655225 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT01655225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01655225 about?
NCT01655225 is a clinical study titled "A Study of LY3023414 in Participants With Advanced Cancer". The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer. The study will also explore the changes to various markers in blood cells and potentially tumor cells. Finally, the study will h...
What is the current status of trial NCT01655225?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 156 participants. The study started on 2012-07-31. Estimated completion is 2022-02-02.
What interventions are being tested in trial NCT01655225?
The interventions under investigation include: Cisplatin (DRUG), Pemetrexed (DRUG), Midazolam (DRUG), Fulvestrant (DRUG), LY3023414 (DRUG).
Who is sponsoring clinical trial NCT01655225?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.